CD274 and lung carcinoma: A large number of clinical trials have demonstrated that immunotherapy can bring greater clinical benefit to patients with PD-L1 ≥50% and has rapidly become the standard management of advanced lung cancer (Ettinger et al., 2021; Herbst et al., 2020; Reck et al., 2016; Mok et al., 2019).